Chromatin control of environmental stress response

Lead Research Organisation: University of Cambridge
Department Name: UNLISTED

Abstract

Our research will have two important implications. First, our work on toxicological effects of current therapeutics will provide molecular basis of 'side-effects' in patients. We focus on therapeutics in clinical trials targeting cellular protein-folding machinery in cancer cells. By understanding the unintended targets of these drugs in normal cells, our work will allow a better design of future drugs. Second, our work on environmental toxins will provide molecular framework for the bioassay and potential mitigation strategies to deal with toxic exposure. We focus on heavy metal toxins that are routinely found as industrial and natural contaminants in drinking water and food, affecting human as well as other animals and plants.

Technical Summary

Cells respond to environmental stress and toxins by mounting an adaptive stress response in order to survive stressful conditions. Transcriptional control is a major regulatory layer that determines the strength, the duration and persistence of cellular stress response. Transcription factors, chromatin modifications and non-coding RNA influence the transcriptional response to environmental stress. The molecular mechanisms by which chromatin exerts control over stress response is the main focus of the Unit programme. We aim to address the following questions:
(i) Which cellular pathways sense environmental stress/ toxins and signal to the genome?
(ii) How does chromatin interpret the information about cellular health and toxic exposure determining the transcriptional response to stress?
(iii) How does the transcriptional response adapt cellular phenotypes to survive the stress?
We study these three questions in the context of cellular exposure to environmental stress as well as small-molecule therapeutics in collaboration with pharmaceutical companies. Our approaches include genomics, single-cell transcriptomics, proteomics, chromatin biochemistry as well as genome-wide screening to identify novel components of stress-response pathways. Discovery-driven global approaches in mammalian cells are further validated by in vitro reconstitution experiments and mouse genetic models. We aim to gain novel insights and mechanistic understanding of transcriptional response to environmental toxins. In addition, our research will shed light on unintended toxicological effects of therapeutics. With the approach of understanding molecular basis of toxic effects, our research will suggest ways of mitigating with stress and toxicity.

Publications

10 25 50

Related Projects

Project Reference Relationship Related To Start End Award Value
MC_UU_00025/1 01/04/2018 31/07/2020 £1,680,000
MC_UU_00025/2 Transfer MC_UU_00025/1 01/04/2018 30/09/2020 £3,488,000
MC_UU_00025/3 Transfer MC_UU_00025/2 01/04/2018 31/03/2024 £2,873,000
MC_UU_00025/4 Transfer MC_UU_00025/3 01/04/2018 31/03/2024 £3,108,000
MC_UU_00025/5 Transfer MC_UU_00025/4 01/04/2018 31/03/2024 £2,200,000
MC_UU_00025/6 Transfer MC_UU_00025/5 01/04/2018 31/05/2019 £76,000
MC_UU_00025/7 Transfer MC_UU_00025/6 01/04/2018 31/03/2024 £2,547,000
MC_UU_00025/8 Transfer MC_UU_00025/7 01/10/2019 31/03/2024 £2,438,000
MC_UU_00025/9 Transfer MC_UU_00025/8 01/09/2019 31/03/2024 £1,721,000
 
Description ERC Consolidator Grant
Amount € 1,992,500 (EUR)
Funding ID 819753 - ChaperoneRegulome 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 01/2020 
End 12/2024
 
Description Elucidating cellular mechanisms underlying adverse versus adaptive response to environmental chemicals
Amount £105,984 (GBP)
Funding ID BB/X511419/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 09/2022 
End 09/2026
 
Description TransNAT
Amount £8,000,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 12/2022 
End 11/2025
 
Description iMed Postdosctoral fellowship
Amount € 140,000 (EUR)
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start 04/2022 
End 03/2025